NervGen Pharma
(TSXV) NGEN
NervGen Pharma Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$44.12M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
NGEN News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout NervGen Pharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
8
CEO
Adam Rogers, MD
Website
www.nervgen.comHeadquarters
Vancouver, BC V5M 4X6, CA
NGEN Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-175%
Return on Capital
-7%
Return on Assets
-2%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$25.08M
EBITDA
$25.02M
Operating Cash Flow
$19.50M
Capital Expenditure
$0.00
Free Cash Flow
$19.50M
Cash & ST Invst.
$22.08M
Total Debt
$8.37K
NervGen Pharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
11
N/A
Net Income
$26.91M
-212.6%
EBITDA
$6.39M
+5.9%
Quarterly Fundamentals
Net Cash
$22.07M
+27.9%
Accounts Receivable
$80.83K
-80.5%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$8.37K
-91.4%
Return on Assets
-1.90%
N/A
Return on Invested Capital
-7.21%
N/A
Free Cash Flow
$6.40M
-74.8%
Operating Cash Flow
$6.40M
-74.8%